Govt. seeks to cut access to substandard medicines

1. At a Glance

• The Union Health Ministry has published draft amendments to the Drugs Rules, 1945. Under them, a drug's manufacturing licence would be suspended immediately once the drug is declared Not of Standard Quality (NSQ) on specified critical quality parameters [1].
• The aim is to close a regulatory time gap. Under current rules, a show-cause notice and other prescribed steps must come before any suspension, and the NSQ drug stays on the market meanwhile [1].
• It is relevant for UPSC in several areas: drug regulation, public health safety, pharma exports ("Pharmacy of the World" image), Centre–State regulatory roles, and natural justice versus public interest.
• Globally, the WHO says at least 1 in 10 medicines in low- and middle-income countries (LMICs) are substandard or falsified [2].

2. Why in the News

• The Hindu, 5 Nov 2026: the Union Health Ministry proposed amendments to the Drugs Rules, 1945 so that manufacturing licences of NSQ drugs can be suspended at once on critical parameters [1].
• The draft is open for public consultation. Objections and suggestions are due within 30 days of the date copies of the Gazette of India carrying the draft are made available to the public [1].
• Under the current process, a drug may remain in circulation between the NSQ declaration and regulatory action, which poses "potential risks to public health" [1].

3. Background & Evolution

• The Drugs Rules, 1945 are the main rules on drug manufacturing licences, sale and quality. The article does not name their parent Act; it is the Drugs and Cosmetics Act, 1940, which my searches did not cover.
• Existing procedure: suspension or cancellation of a manufacturing licence comes after the prescribed regulatory steps, including a show-cause notice [1].
• Earlier milestones:
• Parliamentary records list amendments to the Drugs Rules, including G.S.R. 823(E) dated 17.11.2022 [3].

• G.S.R. 922(E) dated 28.12.2023 revised Schedule M (Good Manufacturing Practices) [3].

• Global milestone: the WHO launched the Global Surveillance and Monitoring System (GSMS) in 2013 to improve detection, reporting and response to substandard and falsified (SF) medical products [2].

• Nov 2026: the draft rule on immediate suspension of NSQ manufacturing licences was published [1].

4. Core Static Facts

• NSQ vs Spurious (Indian usage): NSQ means a drug fails quality standards, which matches the WHO's "substandard". Spurious is close to the WHO's "falsified", where deception is the defining element [2].

5. Multi-Dimensional Analysis

Legal / Constitutional

• The change moves from "hear first, act later" to "act first, hear later" for critical failures. This is a deliberate trade-off between audi alteram partem (the right to be heard) and the right to health under Art. 21 [1].
• It is done through delegated legislation (a rule amendment with prior public consultation in the Gazette), not through amending the Act [1].
• Natural justice is kept partly intact because only "specified critical quality parameters" trigger it. Rules that are too broad would invite legal challenge [1].

Governance / Ethical

• It closes the window in which a drug already known to be NSQ is still in circulation [1].
• It shows a precautionary principle in regulation: protecting patients comes before the manufacturer's procedural convenience.
• Transparency: public consultation lets industry, patient groups and states give input [1].

Economic

• India's credibility as an exporter of generic medicines depends on its quality reputation. SF products cost health systems an estimated US$ 30.5 bn a year worldwide [2].
• Small and medium manufacturers face a higher compliance burden, which links to the revised Schedule M GMP norms [3].

Social / Public Health

• SF medicines cause treatment failure, antimicrobial resistance, and loss of trust in health systems. The poor in LMICs bear most of the harm [2].
• Online sales through unauthorised sites make it easier for falsified products to reach consumers [2].

Administrative

• Implementation depends on consistent testing and NSQ declarations by Central and State drug-testing laboratories, and on coordination between them.
• Risks: uneven lab capacity, delays in confirmatory testing, and disputes over test results after suspension.

Scientific / Technological

• In May 2025, the WHO published a report on technologies for screening and detecting SF products. It flagged both progress and persistent gaps [4].

6. Recent Developments (last 12–18 months)

• Dec 2024: the WHO updated its fact sheet on SF medical products, including the 1-in-10 figure for LMICs and the US$ 30.5 bn estimate [2].
• 9 May 2025: the WHO released a report on gaps and opportunities in SF product detection technologies [4].
• Nov 2026: the Health Ministry published draft Drugs Rules amendments for immediate suspension of NSQ manufacturing licences, with a 30-day consultation [1].

7. Prelims Hooks

• The draft amendment is to the Drugs Rules, 1945, not the Drugs and Cosmetics Act, 1940 itself [1].
• Proposing body: Union Ministry of Health & Family Welfare [1].
• Trigger: a drug declared NSQ on specified critical quality parameters, not any NSQ finding [1].
• Proposed action: immediate suspension of the manufacturing licence, with no prior show-cause notice [1].
• Existing rule: suspension or cancellation comes after the prescribed procedure, including a show-cause notice [1].
• Public consultation period: 30 days from the date the Gazette of India copies are made public [1].
• Schedule M of the Drugs Rules covers Good Manufacturing Practices. It was revised by G.S.R. 922(E), dated 28 Dec 2023 [3].
• WHO: at least 1 in 10 medicines in LMICs are substandard or falsified [2].
• WHO estimate: about US$ 30.5 billion per year spent on SF products [2].
• Substandard products are authorised products that fail their standards, also called "out of specification" [2].
• Falsified products deliberately misrepresent their identity, composition or source [2].
• The WHO Global Surveillance and Monitoring System was launched in 2013 [2].
• The WHO Member State Mechanism works to prevent and control SF medical products [2].

8. Why Faster Suspension Still Comes Too Late for Most Patients

• The longest delay is in the lab, not in the show-cause notice
• The draft speeds up the step after a drug is declared NSQ [1].
• But a drug can only be declared NSQ after the lab report arrives. That report is often very late.
• A CAG audit of Haryana's state drug supply found that in 7,947 of 7,975 NSQ cases, warehouses had already sent the drugs to hospitals before the test report came back [5].

• Those reports arrived anywhere from 1 to 595 days after the drugs were sent out [5]. By then, most of the batch had already been used by patients.

• Suspending a licence stops new production, not old stock

• Suspending a manufacturing licence stops the factory from making more of the drug.
• On its own, it does not bring back batches already sitting in pharmacies and hospital stores. That needs a separate recall.

• So the rule fixes only part of the "drug stays in circulation" problem the Ministry itself describes [1].

• The size of the problem

• In 2024-25, 3,104 cases of NSQ drugs and 245 cases of spurious drugs were reported [9].
• If every one of these first needs a show-cause notice and a reply, the process will be slow. This is the strongest reason for the reform. It also shows how much testing has to happen quickly.

9. Who Will Actually Use the Power: Thin Staff in the States

• The power is used mostly by State licensing authorities
• Action after inspections, such as suspending or cancelling a licence, is taken by State licensing authorities [8].

• So the new rule will only be as strong as the weakest State drug controller's office.

• Too few inspectors

• As of December 2023, only 201 drug inspectors were in post against 504 sanctioned posts [6].

• With fewer than half the posts filled, it is hard to collect samples, follow up on suspensions, and check whether a factory has fixed its problems.

• New labs are at risk of stalling

• A Parliamentary Standing Committee found that the scheme for Strengthening of State Drug Regulatory Systems (SSDRS) raised testing capacity. But a lack of staff in the States limits what it achieves [7].

• The committee asked for interim funding so that 19 new and 28 upgraded State drug-testing labs do not stall while the revised scheme waits for approval [7].

• States do not apply the same standards

• The Drugs Consultative Committee (DCC, a Centre–State advisory body on drug regulation) noted that some States lag in applying drug standards uniformly, in lab testing facilities, and in staff skills [11].
• The result: a drug that fails in one State may face immediate suspension there, while the same failure goes unchecked in another.

10. The Case Against 'Act First' and Why It Mostly Fails

• The strongest objection: one lab result can be wrong
• If the test is faulty, a manufacturer loses production and reputation before anyone hears its side.
• This worry is real. A Rajya Sabha Standing Committee in 2007 listed problems in government drug labs: lack of sophisticated instruments, too few trained analysts, shortage of reagents, and test methods that were not validated (not proven to give reliable results) [13].

• Small and medium firms (MSMEs) are hit hardest, because they have the least money to survive a shutdown while they contest the result.

• Why the objection does not win

• Suspension is not cancellation. It is temporary and can be reversed.
• Regulators already suspend licences quickly after inspections. Of about 400 units inspected, nearly 36% had to be closed for failing standards [10].
• Inspections of 400 premises, including MSMEs, led to more than 300 regulatory actions [8]. Suspension without a long process is therefore already in use.

• The draft limits immediate action to specified critical parameters [1]. A dangerous failure, such as toxic contamination, cannot wait for a hearing.

• What the objection gets right

• Fast action is fair only if the right of appeal is also fast. The draft as reported does not set a deadline for re-testing or for deciding a challenge [1].
• If that deadline is missing, a wrong lab result can keep a firm shut for months.

11. What the Final Rule and the States Must Add

• Health Ministry: publish the 'critical parameters' list in the rule itself
• Immediate suspension is triggered only by failure on specified critical parameters [1].

• If that list is vague or left to officials to decide, State controllers will apply it differently. Firms will then go to court on grounds of arbitrariness.

• Health Ministry: set a fixed time for re-testing and a clear path back

• CDSCO already lets a firm restart only after it finds the root cause, makes corrective changes, and proves they work with validated data [12].

• The final rule should use the same path for NSQ suspensions, with a time limit for the confirmatory test.

• State medical supply corporations: do not send out stock before the test report arrives

• The Haryana audit shows what happens otherwise: almost every NSQ batch had already reached hospitals [5].

• Without this step, faster suspension at the factory protects very few patients.

• Union Government: fund SSDRS without a gap and fill inspector posts

• Follow the Parliamentary Standing Committee's call for interim funding of the 47 new and upgraded State labs [7].

• Fill the 303 vacant drug-inspector posts (504 sanctioned minus 201 in post) [6].

• Link suspension to recall and global reporting

• Every immediate suspension should come with a batch recall order.
• It should also be reported to the WHO Global Surveillance and Monitoring System, so that importing countries learn of it quickly [2]. This protects India's export reputation.

12. Anchors for Answers

• Data: In a CAG audit of Haryana, 7,947 of 7,975 NSQ drug cases had reached hospitals before the lab report came back; reports took 1–595 days [5]
• Data: 3,104 NSQ and 245 spurious drug cases reported in 2024-25 [9]
• Data: 201 drug inspectors in post against 504 sanctioned (Dec 2023) [6]
• Data: WHO: at least 1 in 10 medicines in LMICs are substandard or falsified; about US$ 30.5 bn a year spent on them [2]
• Report/Committee: Parliamentary Standing Committee on Health on the SSDRS scheme (2026): staff shortages in States; interim funding needed for 19 new and 28 upgraded State labs [7]
• Report/Committee: Rajya Sabha Standing Committee on the Drugs and Cosmetics (Amendment) Bill, 2007: weak government drug labs (instruments, analysts, reagents, non-validated methods) [13]
• Report/Committee: CAG performance audit on public health, Haryana (2024), on drug supply and quality testing [5]
• Law/Case: Drugs and Cosmetics Act, 1940 (parent Act) and Drugs Rules, 1945 (delegated legislation); Article 21 right to health versus audi alteram partem; Maneka Gandhi v. Union of India (1978) accepted that in urgent cases a hearing can come after the action (post-decisional hearing)
• Scheme: Strengthening of State Drug Regulatory Systems (SSDRS): builds State testing labs, which decide how fast a drug can be declared NSQ [7]
• Scheme: Risk-based inspections by CDSCO with State controllers: 400 premises inspected, more than 300 actions, showing quick suspension is already in practice [8]

13. Mains Relevance

• GS-II: issues in the development and management of Health as a social sector; government policies and interventions; statutory and regulatory bodies.
• GS-III: science and technology in everyday life; the industrial sector (pharmaceuticals); export competitiveness.
• GS-IV: public interest versus procedural fairness; corporate ethics in pharma.
• Question stems: 1. The time lag between declaring a drug 'Not of Standard Quality' and regulatory action is a public-health hazard. Critically examine the proposed amendments to the Drugs Rules, 1945 in this context. (GS-II, 15 marks) 2. India's image as the 'Pharmacy of the World' depends on the robustness of its domestic quality regulation. Discuss the reforms needed. (GS-III) 3. Does immediate suspension of licences without a show-cause notice violate principles of natural justice? Analyse with reference to the right to health. (GS-II/IV)

14. Related Topics to Study Next

• Drugs and Cosmetics Act, 1940 and the proposed new Drugs, Medical Devices and Cosmetics Bill: the parent law and the planned replacement framework.
• CDSCO and the DCGI: the central regulator, which publishes monthly NSQ and spurious drug alerts.
• Revised Schedule M (GMP): quality standards meant to stop NSQ drugs at the source [3].
• Cough-syrup contamination episodes (DEG/EG contamination): the trigger for global scrutiny of Indian pharma exports.
• WHO GSMS and the Member State Mechanism: global surveillance architecture [2].
• Antimicrobial resistance: substandard antibiotics speed up resistance [2].
• Online pharmacies / e-pharmacy regulation: an emerging channel for falsified drugs [2].
• Jan Aushadhi and generic drug quality: public trust in low-cost generics.

15. NCERT Concepts to Revise

• Drugs and Cosmetics Act, 1940 (Polity): The parent Act under which the Drugs Rules, 1945 are made; knowing it clarifies Act versus Rules.
• Delegated legislation (Polity): The change is made by amending executive-made rules, not the Act, so you must know how such rules work.
• Principles of natural justice (Polity): Suspending a licence before a show-cause notice cuts into the right to be heard.
• Right to health (Polity): Public safety from bad medicines is the Article 21 interest weighed against the manufacturer's procedural rights.
• Central Drugs Standard Control Organisation (Polity): CDSCO is the national drug regulator that sets standards and, with State controllers, declares drugs NSQ.
• Precautionary principle (Economy): Acting at once on critical failures to protect patients reflects the precautionary approach to regulation.

16. Common Errors / Trap Areas

• Act vs Rules: the amendment is to the Drugs Rules, 1945, which are subordinate legislation, not to the Drugs and Cosmetics Act, 1940 [1].
• NSQ ≠ Spurious / Falsified: NSQ (substandard) is a quality failure of an authorised product. Falsified or spurious involves deliberate misrepresentation [2].
• Scope: immediate suspension applies only to failures on specified critical parameters, not every NSQ finding [1].
• Status: these are draft rules out for 30-day consultation, not yet final [1].
• Schedule confusion: Schedule M is GMP, not to be confused with Schedule H (prescription drugs) or other schedules [3].